Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab.

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Original language	English
Title of host publication	Adverse Reactions to Biologics
Pages	70
Number of pages	12
DOIs	https://doi.org/10.1159/000478079
Publication status	Published - 2018

Name	Current problems in dermatology

Fields of science

This output contributes to the following UN Sustainable Development Goals (SDGs)

@inbook{2fcc60c13eb94b9898aaf14912cf74b3,

title = "Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab.",

author = "I. Saulite and Emmanuella Guenova and Wolfram H{\"o}tzenecker",

year = "2018",

doi = "10.1159/000478079",

language = "English",

series = "Current problems in dermatology",

pages = "70",

booktitle = "Adverse Reactions to Biologics",

}

TY - CHAP

T1 - Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab.

AU - Saulite, I.

AU - Guenova, Emmanuella

AU - Hötzenecker, Wolfram

PY - 2018

Y1 - 2018

UR - https://www.ncbi.nlm.nih.gov/pubmed/29131039

U2 - 10.1159/000478079

DO - 10.1159/000478079

M3 - Chapter

T3 - Current problems in dermatology

SP - 70

BT - Adverse Reactions to Biologics

ER -